Literature DB >> 11908941

CD40/CD40L interaction is essential for the induction of EAE in the absence of CD28-mediated co-stimulation.

Ann M Girvin1, Mauro C Dal Canto, Stephen D Miller.   

Abstract

CD28 provides a co-stimulatory signal critical for optimal T cell activation. We and others have shown that the B7/CD28 co-stimulatory pathway is a major regulatory pathway for the control of immune responses. Experimentally induced models of autoimmunity have been shown to be prevented or reduced in intensity in mice deficient for CD28. Here, we show that EAE and accompanying neuroantigen-specific immune responses are drastically reduced in the absence of CD28. However, we go on to show that EAE can be induced in CD28-deficient mice following two immunizations. After re-immunization, CD28-deficient mice develop severe EAE with myelin-specific responses equal to those of wildtype controls, and extensive demyelination in the spinal cord. Treatment of CD28-deficient mice with anti-CD40L at the time of immunization significantly reduced DTH responses and prevented the development of EAE following two immunizations, indicating a critical role for CD40/CD40L signaling in the absence of CD28. Taken together, our results indicate that CD28-mediated co-stimulation does not regulate immunological anergy. Instead, CD28 appears to adjust the threshold for activation and expansion of autoreactive cells. Copyright 2002 Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11908941     DOI: 10.1006/jaut.2001.0573

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  19 in total

1.  Normal Th1 development following long-term therapeutic blockade of CD154-CD40 in experimental autoimmune encephalomyelitis.

Authors:  Laurence M Howard; Serge Ostrovidov; Cassandra E Smith; Mauro C Dal Canto; Stephen D Miller
Journal:  J Clin Invest       Date:  2002-01       Impact factor: 14.808

Review 2.  Immune modulating peptides for the treatment and suppression of multiple sclerosis.

Authors:  Ahmed H Badawi; Teruna J Siahaan
Journal:  Clin Immunol       Date:  2012-06-05       Impact factor: 3.969

3.  A CD40 targeting peptide prevents severe symptoms in experimental autoimmune encephalomyelitis.

Authors:  Gisela M Vaitaitis; Martin G Yussman; David H Wagner
Journal:  J Neuroimmunol       Date:  2019-03-21       Impact factor: 3.478

4.  Immune tolerance induced by intravenous transfer of immature dendritic cells via up-regulating numbers of suppressive IL-10(+) IFN-γ(+)-producing CD4(+) T cells.

Authors:  Fang Zhou; Bogoljub Ciric; Guang-Xian Zhang; Abdolmohamad Rostami
Journal:  Immunol Res       Date:  2013-05       Impact factor: 2.829

Review 5.  Emerging therapies to target CNS pathophysiology in multiple sclerosis.

Authors:  Jiwon Oh; Amit Bar-Or
Journal:  Nat Rev Neurol       Date:  2022-06-13       Impact factor: 44.711

Review 6.  Emerging immunopharmacological targets in multiple sclerosis.

Authors:  Mojtaba Farjam; Guang-Xian Zhang; Bogoljub Ciric; Abdolmohamad Rostami
Journal:  J Neurol Sci       Date:  2015-09-14       Impact factor: 3.181

7.  Defining a new biomarker for the autoimmune component of Multiple Sclerosis: Th40 cells.

Authors:  Dan M Waid; Teri Schreiner; Gisela Vaitaitis; Jessica R Carter; John R Corboy; David H Wagner
Journal:  J Neuroimmunol       Date:  2014-03-15       Impact factor: 3.478

Review 8.  Macrophages: a double-edged sword in experimental autoimmune encephalomyelitis.

Authors:  Zhilong Jiang; Jack X Jiang; Guang-Xian Zhang
Journal:  Immunol Lett       Date:  2014-03-31       Impact factor: 3.685

9.  Local administration of soluble CD40:Fc to the salivary glands of non-obese diabetic mice does not ameliorate autoimmune inflammation.

Authors:  Nienke Roescher; Jelle L Vosters; Zhenan Lai; Toshimitsu Uede; Paul P Tak; John A Chiorini
Journal:  PLoS One       Date:  2012-12-26       Impact factor: 3.240

Review 10.  Role of Tumor Necrosis Factor Superfamily in Neuroinflammation and Autoimmunity.

Authors:  Sandip Sonar; Girdhari Lal
Journal:  Front Immunol       Date:  2015-07-20       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.